Implantation of the phakic intraocular implantable collamer lens (ICL) for correction of paediatric unilateral high myopia: 3 year follow-up

Session Details

Session Title: Presented Poster Session: Refractive Surgery New Techniques/Instrumentation/Devices III

Venue: Poster Village: Pod 2

First Author: : M.Abdellah EGYPT

Co Author(s): :    E. Mostafa                       

Abstract Details

Purpose:

To evaluate the safety and efficacy of implantable collamer lens in the management of unilateral high myopia in children who are difficult to be treated by spectacle and contact lenses.

Setting:

Ophthalmology Department , Sohag University Hospital

Methods:

Prospective non randomized study, 17 children included in this study (10 females, 7 males), mean age is 8.3 +2.7 years old, (5.5 to 13 years ). The mean spherical equivalent (-11.2+4.1), the mean BCVA was 0.3 Mean Axial length was (25.22 + 4.14 mm), mean Anterior chamber depth was (3.42 +0.32 um), mean WTW was 11.2 + 0.37 mm, Amblyopia (76.4%), strabismus (52.94%), magnified fundus examination, OCT macula were done. Under general anesthesia with implantation of central flow ICL with aiming of emmetropia postoperative, UCVA, Refraction, ICL Vault , IOP measurement, were Reported every 6 months up to three years.

Results:

Postoperative refraction was +0.5 + 0.75 D, efficacy (mean postoperative UCVA / mean preoperative BCVA ) was 97% in 1st months and 133% at the end of three years , mean ICL Vault was 0.63+0.15 at 1st month to 0.62+21 at the end of 3 years change (p= 0.24), 7 of 13 amblyopic eyes (53.8%) gained 1 line or more improvement 45.4% of squinted eyes 5 of 11 eyes showed improvement, at 3rd year follow up, 2 eyes ( 11.7%) showed refraction change > 3 Diopters , one case is planned for ICL exchange No postoperative cataract nor retinal complications.

Conclusions:

Implantable collamer lens implantation is safe , effective and changeable for correction of unilateral high myopia in children who are not compliance to spectacles or contact lens wear.

Financial Disclosure:

None